Clone Wars: Quantitatively Understanding Cancer Drug Resistance.

Area of Science:

• Oncology
• Mathematical Biology
• Clinical Trial Design

Background:

• Early clinical development for cancer treatments aims to predict efficacy and determine safe therapeutic doses for Phase II trials.
• Mathematical models linking early radiologic tumor response (6-8 weeks) to overall survival have shown limited success.
• Interpreting early treatment signals requires a deeper understanding of tumor dynamics.

Purpose of the Study:

• To propose a novel approach for interpreting early efficacy signals in cancer therapy development.
• To enhance the predictive power of mathematical models used in early-phase clinical trials.
• To optimize cancer treatment strategies by considering tumor evolutionary dynamics.

Main Methods:

• Reviewing existing literature on mathematical modeling of tumor response and survival.
• Developing a conceptual framework that integrates evolutionary selection pressure into predictive models.
• Analyzing the limitations of current models in capturing complex tumor behavior.

Main Results:

• Current models often fail to accurately predict overall survival from early tumor response.
• Evolutionary selection pressure significantly influences tumor response dynamics.
• A model incorporating evolutionary dynamics offers a more robust interpretation of early efficacy signals.

Conclusions:

• Considering evolutionary selection pressure is essential for accurately interpreting early radiologic tumor response in cancer drug development.
• This approach can lead to more reliable predictions of treatment efficacy and better-informed decisions for advancing therapies.
• Optimizing cancer therapy requires a paradigm shift towards understanding treatment as an evolutionary process.